News Sentiment

ACHV sentiment intelligence

Achieve Life Sciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.11 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-4.5% over one week, +10.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Canaccord reiterates Achieve Life Sciences stock rating on CRL review

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -4.5% Price reacting lower
Trend fit Trend active 10.7% over four weeks
Fair value 46.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 9
Investing.com 5
GlobeNewswire 5
TradingView 4
MarketBeat 2
Seeking Alpha 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 20
Analyst action 4
Regulatory and legal 4
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
timothysykes.com Direct company coverage

Achieve Life Sciences Inc. (ACHV) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Achieve Life Sciences Inc. (ACHV) stock, showing its current price at $6.40 with no change. It notes that there are no analyst ratings or earnings information currently available for ACHV. The article also includes a general disclaime

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 11:39
Source
timothysykes.com
Market source Direct company coverage

Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting

Achieve Life Sciences (NASDAQ: ACHV) held its 2026 annual meeting virtually, where stockholders considered the election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and a non-binding say-on-pay proposal for executive compensation. The most

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 23:39
Source
Market source
Stock Titan Direct company coverage

Vivo Opportunity group reports 5.0% stake in Achieve Life Sciences | ACHV SEC Filing - Form SCHEDULE 13G

Vivo Opportunity Group has reported a 5.0% beneficial ownership stake in Achieve Life Sciences (ACHV) through a SCHEDULE 13G SEC filing. This collective ownership, totaling 5,305,640 shares, includes both currently held common stock and shares issuable upon the exercise of warran

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 20:40
Source
Stock Titan
Seeking Alpha Direct company coverage

Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able (NASDAQ:ACHV)

Achieve Life Sciences (ACHV) has seen significant movement in its stock, including a recent rally, despite a Complete Response Letter (CRL) from the FDA. The author maintains a "strong buy" rating, noting that recent financing, supply chain improvements, and new leadership have d

Tone
Positive 74/100
Event
Analyst action
Published
07 Jul 2026 11:33
Source
Seeking Alpha
Stock Titan Direct company coverage

[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event

ACHIEVE LIFE SCIENCES, INC. filed an 8-K report detailing the outcomes of its annual meeting of stockholders. Key approvals included increasing authorized common stock from 150,000,000 to 300,000,000 shares, the election of nine directors, and the ratification of PricewaterhouseC

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:41
Source
Stock Titan
Stocktwits Direct company coverage

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Achieve Life Sciences (ACHV) shares surged 42% after the company appointed a new CEO and announced a private placement of up to $354 million. This move comes as the company prepares for regulatory approval of its experimental nicotine dependence drug, cytisinicline, despite antic

Tone
Positive 72/100
Event
Regulatory and legal
Published
04 Jul 2026 10:10
Source
Stocktwits
Finviz Direct company coverage

ACHV - Achieve Life Sciences Inc Latest SEC Filings

This article provides a comprehensive overview of Achieve Life Sciences Inc (ACHV), including its latest stock performance data, financial figures, key ratios, and insider/institutional ownership. It details market capitalization, income, sales, per-share values, and various perf

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:40
Source
Finviz
Stock Titan Direct company coverage

Achieve Life Sciences joins Russell 2000 in reconstitution

Achieve Life Sciences (Nasdaq: ACHV) has been added to the Russell 2000 Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The company, which is developing cytisinicline for nicotine dependence, is also a member of the Russell 3000 Index. This inc

Tone
Positive 66/100
Event
Market update
Published
02 Jul 2026 01:42
Source
Stock Titan
GuruFocus Direct company coverage

Achieve Life Sciences (ACHV) Joins Russell 2000 Index

Achieve Life Sciences (ACHV) has been included in the Russell 2000 Index, a significant milestone expected to increase its visibility and institutional investment. Despite this, the company has a low GF Score™ of 32/100, moderate financial strength (5/10), and significant profita

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 14:09
Source
GuruFocus
Investing.com South Africa Direct company coverage

Achieve Life Sciences added to Russell 2000 index By Investing.com

Achieve Life Sciences (NASDAQ:ACHV) has been added to the Russell 2000 Index, reflecting strong investor interest with a 170% return over the past year. The pharmaceutical company is focused on developing cytisinicline for nicotine dependence treatment and is also a member of the

Tone
Positive 64/100
Event
Market update
Published
29 Jun 2026 13:09
Source
Investing.com South Africa
GlobeNewswire Direct company coverage

Achieve Life Sciences Joins Russell 2000® Index

Achieve Life Sciences, a specialty pharmaceutical company focused on treating nicotine dependence with cytisinicline, announced its inclusion in the Russell 2000® Index, effective June 26, 2026. The company is also part of the Russell 3000® Index, significant benchmarks for insti

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 12:09
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of Achieve Life Sciences, Inc. – NASDAQ:ACHV

This article provides financial information for Achieve Life Sciences, Inc. (NASDAQ: ACHV), specifically focusing on its Price to Earnings (forward) metric. It is hosted on TradingView, a financial platform offering various market tools and data.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Achieve Life Sciences, Inc. – NASDAQ:ACHV

This article focuses on the enterprise value to EBITDA forward for Achieve Life Sciences, Inc. (NASDAQ: ACHV). It provides a financial metric for the company as part of a larger financial data overview on TradingView, indicating that specific value details are available through t

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 16:39
Source
TradingView
TradingView Direct company coverage

Achieve Life Sciences, Inc. Actuals & Estimates (NASDAQ:ACHV)

This article provides an overview of Achieve Life Sciences, Inc. (NASDAQ: ACHV) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along wit

Tone
Positive 75/100
Event
Earnings
Published
26 Jun 2026 09:39
Source
TradingView
Investing.com Direct company coverage

Canaccord reiterates Achieve Life Sciences stock rating after CRL

Canaccord Genuity reiterated a Buy rating and a $13.00 price target for Achieve Life Sciences (NASDAQ:ACHV) after the company received a Complete Response Letter (CRL) from the FDA for cytisinicline. The CRL was due to manufacturing issues at a third-party facility and incomplete

Tone
Positive 60/100
Event
Analyst action
Published
23 Jun 2026 13:11
Source
Investing.com
Investing.com Direct company coverage

Wainwright reiterates Achieve Life Sciences stock rating after FDA letter

H.C. Wainwright maintained a Buy rating and $12.00 price target for Achieve Life Sciences (NASDAQ:ACHV) despite the company receiving a Complete Response Letter from the FDA for its cytisinicline drug. The FDA's concerns were related to manufacturing and labeling, not clinical ef

Tone
Positive 59/100
Event
Analyst action
Published
23 Jun 2026 12:09
Source
Investing.com
Investing.com Direct company coverage

Achieve Life Sciences stock falls after FDA issues response letter

Achieve Life Sciences' stock fell after the FDA issued a Complete Response Letter for its New Drug Application for cytisinicline, a nicotine dependence treatment. The letter cited deficiencies at a third-party manufacturing facility and incomplete product labeling, but not issues

Tone
Negative 30/100
Event
Market update
Published
23 Jun 2026 05:40
Source
Investing.com
Simply Wall Street Direct company coverage

Achieve Life Sciences (NasdaqCM:ACHV) Stock Forecast & Analyst Predictions

Achieve Life Sciences (ACHV) is forecast to grow earnings and revenue significantly, with analysts expecting profitability within the next three years, despite some recent setbacks regarding its cytisinicline NDA. The FDA issued a Complete Response Letter for cytisinicline due to

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 18:10
Source
Simply Wall Street
Reuters Direct company coverage

US FDA declines to approve Achieve Life Sciences' smoking-cessation drug

The FDA has declined to approve Achieve Life Sciences' smoking-cessation drug, cytisinicline, due to issues at a third-party manufacturing facility and incomplete product labeling. The company plans to resubmit its application in Q4 2026, with potential FDA approval in the first

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 12:54
Source
Reuters
GlobeNewswire Direct company coverage

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA for its cytisinicline New Drug Application due to manufacturing deficiencies at a third-party facility and uncompleted final product labeling. The FDA identified no issues with the drug's efficacy or cli

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 12:41
Source
GlobeNewswire
Investing.com Direct company coverage

Achieve Life Sciences receives FDA rejection on manufacturing issues

Achieve Life Sciences Inc. received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, citing manufacturing issues at a third-party facility and incomplete product labeling, rather than concerns about the drug's clinical efficacy or safe

Tone
Negative 38/100
Event
Market update
Published
22 Jun 2026 12:39
Source
Investing.com
Stock Titan Direct company coverage

Achieve Life FDA rejects cytisinicline filing over manufacturing issues

Achieve Life Sciences (Nasdaq: ACHV) received a Complete Response Letter (CRL) from the FDA for its cytisinicline NDA due to manufacturing deficiencies at a prior third-party facility and incomplete product labeling. The FDA did not identify any issues with the clinical efficacy

Tone
Negative 37/100
Event
Market update
Published
22 Jun 2026 12:39
Source
Stock Titan
TradingKey Direct company coverage

Achieve Life Sciences Inc (ACHV) Earnings Forecast: Future EPS & Revenue Growth Estimates

Achieve Life Sciences Inc (ACHV) has an earnings forecast score of 8.00, placing it 165th among 389 companies in the Biotechnology & Medical Research industry. Analysts maintain a "Buy" rating for ACHV, with an average price target of $14.00, suggesting a significant upside. The

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 04:09
Source
TradingKey
TradingKey Direct company coverage

Achieve Life Sciences Inc (ACHV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Achieve Life Sciences Inc (ACHV), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. While the stock shows a current price momentum score of 8.96

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 05:39
Source
TradingKey